Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 94-3409596 (I.R.S. Employer Identification No.) 9301 Amberglen Blvd Suite 100 Austin, TX ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdiction of ...

Financial Position - As of December 31, 2022, the company had cash, cash equivalents, and marketable securities totaling $61.0 million, with $35.0 million borrowed under the K2 Loan and Security Agreement[406] - The company has a stockholders' deficit of approximately $(15.1) million, which affects compliance with Nasdaq listing requirements[408] - The company reported an accumulated deficit of $444.8 million as of December 31, 2022[450] - Cash, cash equivalents, and marketable securities totaled $61.0 million as of December 31, 2022, with $35.0 million outstanding under the K2 Loan and Security Agreement[444][446] - Future funding requirements are uncertain, with the company needing to raise additional capital to maintain operations and comply with loan covenants[454] - The company may need to raise additional funds through collaborations, grants, or licensing, which could result in relinquishing valuable rights to technologies or revenue streams[455] Revenue and Expenses - The company has not generated any revenue from product sales and does not expect to until regulatory approval and commercialization of ETB candidates[424] - Total revenue for the year ended December 31, 2022, was $19.754 million, a decrease of 49% compared to $38.697 million in 2021[433] - Research and development revenue from related parties dropped to $0 in 2022 from $13.136 million in 2021, marking a 100% decrease[433][434] - Total operating expenses decreased by 9% to $108.625 million in 2022 from $118.771 million in 2021[436] - Research and development expenses slightly decreased by 3% to $82.425 million in 2022, with program costs down by $4.1 million[437][438] - General and administrative expenses decreased by $7.9 million, or 23%, to $26.200 million in 2022[441] - Revenue primarily consists of research and development revenue from collaboration partners and governmental grants, recognized as allowable costs are incurred[458] Strategic Changes - The company anticipates a reduction in workforce from approximately 222 employees to about 50% as part of a strategic reprioritization, focusing on clinical development programs for MT-6402, MT-8421, and MT-0169[407] - The strategic reprioritization is expected to incur approximately $0.4 million in costs related to severance pay and other termination benefits[407] - The company is working to regain compliance with Nasdaq listing requirements, potentially through a reverse stock split and raising capital[409] Research and Development - The company expects research and development expenses to increase as it advances the clinical development of its ETB candidates, with significant uncertainties regarding costs and timelines[429] - The company is subject to a Cancer Research Grant Contract with CPRIT, which awarded approximately $15.2 million for research on a CD38-targeting ETB[419] - The company assesses collaboration arrangements under ASC 808 to determine if they involve joint operating activities and significant risks and rewards[459] - Research and development expenses are estimated based on contracts and services performed, with adjustments made as necessary[468] Income and Taxation - Interest and other income increased by 128% to $988,000 in 2022, while interest expense rose by 42% to $4.782 million[442][443] - Deferred tax assets are recorded based on the likelihood of realization, with a valuation allowance provided due to historical net losses[471] - Stock-based compensation is recognized on a straight-line basis over the requisite service periods of the awards[473] Compliance and Reporting - The company has no off-balance sheet arrangements during the periods presented[475] - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[476]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 9301 Amberglen Blvd Suite 100 Austin, TX 78729 (Address of principal executive offices) 78729 (Zip Code) For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (E ...

XXX tem MOLECULAR TEMPLATES NEXT GENERATION IMMUNOTOXINS Corporate Presentation Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relating to the development of MT-6402, MT-5111, MT-0169, and MT-8421 and our next generation ETBs and preclinical pipeline; statements regarding the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMPLATES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 9301 Amberglen Blvd, Suite 100, Austin TX 78729 78729 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT ...

XXX tem MOLECULAR TEMPLATES NEXT GENERATION IMMUNOTOXINS Cowen Presentation Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relating to the development of MT-5111, MT-0169, and MT-6402, and our preclinical pipeline; statements regarding the safety or potential efficacy of our d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3409596 (State or other jurisdiction of incorporation or organization ...

MOLECULAR TEMPLATES Corporate Presentation I 2021 Oppenheimer Healthcare Conference (NASDAQ: MTEM) Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relating to the development of MT-5111, TAK-169, and MT-6402, and our preclinical pipeline; our utilization of a next-generation ET ...